Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
Novartis AG (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP)...
Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the Center for Drug Evaluation (CDE)...
Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Brii Biosciences (HKG: 2137) unveiled a cross-study pooled analysis of hepatitis B surface antigen (HBsAg)...
CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration (FDA)...
Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) announced a landmark collaboration with Mark Cuban...
Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced regulatory clearance from Australia’s Therapeutic Goods Administration (TGA)...
Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ)...
AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request
AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved...
Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
Beijing QL Biopharmaceutical Co., Ltd., a clinical-stage biotech founded in 2018, has filed a prospectus...
Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
Boehringer Ingelheim, the German pharmaceutical giant, officially launched the Pulmonary Fibrosis Care Initiative late last...
Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
Sanofi (NASDAQ: SNY) announced on 24 April 2026 that the European Medicines Agency’s Committee for...
China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest...
Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Novartis AG (NYSE: NVS) announced the voluntary withdrawal of its Type II variation application to...
Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology
Johnson & Johnson (J&J, NYSE: JNJ) announced on 24 April 2026 a definitive agreement to...
NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
China’s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations...
Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) announced a definitive agreement to acquire Organon & Co....
AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has granted approvals...
Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection...
Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Star Sports Medicine Co., Ltd., a Chinese sports medical device manufacturer, successfully completed its initial...
Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China’s National...